Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215436 · ClinicalTrials.gov registry record · Phase 3
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD
A Phase 3 study of COPD, sponsored by Dey.
- Completed
- Registry status
- Phase 3
- Development phase
- 345
- Enrollment target
- 20
- Study locations
NCT00215436 is a Phase 3 study of COPD that has completed, run by Dey. The registered enrollment target is 345 participants, below the 2,414-participant average among 85 other COPD trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT00215436, a Phase 3 study of COPD, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 345 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
Conditions Studied
Interventions
- DRUG Formoterol Fumarate
Study Locations (20)
California
- Research Site - Buena Park
- Research Site - Huntington Beach
- Research Site - Long Beach
- Research Site - Long Beach
- Research Site - Los Angeles
- Research Site - San Diego
- Research Site - Stockton
Florida
- Research Site - Clearwater
- Research Site - DeLand
- Research Site - Tampa
Arizona
- Research Site - Phoenix
- Research Site - Tuscon
Colorado
- Research Site - Denver
- Research Site - Wheat Ridge
Illinois
- Research Site - Hines
- Research Site - Normal
Alabama
- Research Site - Jasper
Connecticut
- Research Site - Hartford
Georgia
- Research Site - Woodstock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00215436
The ClinicalTrials.gov registry entry for NCT00215436 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,414-participant average among 85 other COPD trials with a reported enrollment target (86% lower). The listed sponsor is Dey, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 1 intervention - of which Formoterol Fumarate is the first listed.
NCT00215436 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00215436 about?
NCT00215436 is a clinical study titled "A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD". The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
What is the current status of trial NCT00215436?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 345 participants. The study started on 2005-03. Estimated completion is 2006-09.
What conditions does trial NCT00215436 study?
This clinical trial studies the following conditions: COPD.
What interventions are being tested in trial NCT00215436?
The interventions under investigation include: Formoterol Fumarate (DRUG).
Who is sponsoring clinical trial NCT00215436?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00215436 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
COMPLETED · Phase 3
-
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
RECRUITING · NA
-
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
RECRUITING · NA
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.